Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 03.11.2025 1 Am J Respir Cell Mol Biol 1 Ann Surg Oncol 2 Ann Thorac Surg 5 Anticancer Res 1 Arch Bronconeumol 1 Arch Pathol Lab Med 3 BMC Cancer 3 Br J Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 2 Carcinogenesis 5 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 Int J Cancer 2 J Cancer Res Clin Oncol 2 J Thorac Oncol 1 Lancet Oncol 4 Lung Cancer 2 N Engl J Med 2 Oncogene 2 Oncologist 3 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Respir Cell Mol Biol

1. XU L, Zhou B, Jin K, Ge T, et al
   HDLBP Promotes Glycolysis and CD8(+) T Cell Exhaustion in Lung Adenocarcinoma by Stabilizing GJB2 RNA.
   Am J Respir Cell Mol Biol. 2025;73:780-789.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ZOU FW, Shi SH, Wu C, Zhang ZM, et al
   circ_PPAPDC1A is Associated with Brain Metastasis of Non-Small-Cell Lung Cancer via the miR-30a-3p/SPOCK1 Pathway.
   Ann Surg Oncol. 2025 Oct 24. doi: 10.1245/s10434-025-18476.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

3. SEITLINGER J, Salko O, Bulgarelli Maqueda L, Meng A, et al
   Neoadjuvant chemo-immunotherapy in Non-Small Cell Lung Cancer: Can Positron Emission Tomography scan predict complete pathological response?
   Ann Thorac Surg. 2025 Oct 28:S0003-4975(25)01054.
   PubMed         Abstract available
   
   
4. BROWNLEE AR, Perez C, Weiser L, Yu W, et al
   1121 Shape-sensing Robotic-assisted Bronchoscopic Biopsies: Diagnostic Yield and Surgical Implications.
   Ann Thorac Surg. 2025;120:928-936.
   PubMed         Abstract available
   
   

   
   Anticancer Res

5. KANG JK, Jung JY, Jang WI, Shin YJ, et al
   Comparative Analysis of Dynamic Conformal Arc Therapy and Volumetric-modulated Arc Therapy in Lung Stereotactic Body Radiation Therapy: Evaluating Dosimetric Performance, Treatment Delivery Efficiency, and Plan Robustness.
   Anticancer Res. 2025;45:5121-5138.
   PubMed         Abstract available
   
   
6. KIM HM, Kim JY, Lee CG, Song JY, et al
   Nodal Modulator Regulates Chemo- and Radioresistance in Lung Cancer via the Chk2 Pathway.
   Anticancer Res. 2025;45:4817-4826.
   PubMed         Abstract available
   
   
7. IWAHASHI Y, Tamiya A, Tanaka T, Tamiya M, et al
   Association Between Administration Timing and Efficacy of Nivolumab in Non-small Cell Lung Cancer Treatment.
   Anticancer Res. 2025;45:5077-5084.
   PubMed         Abstract available
   
   
8. SASADA A, Kawachi H, Yamada T, Hata T, et al
   Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
   Anticancer Res. 2025;45:5045-5057.
   PubMed         Abstract available
   
   
9. LEE CY, Fu YK, Yeh CC, Kuo LK, et al
   Combined Treatment of Cisplatin With Caffeic Acid Phenethyl Ester Demonstrates Additive Growth Inhibition on Non-small Cell Lung Cancer Cells.
   Anticancer Res. 2025;45:4971-4986.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

10. TORRES-CADAVID E, Candal-Pedreira C, Ruano-Ravina A, Kelsey K, et al
    Is the Effect of Occupation on Lung Cancer Modified by Tobacco Use and Residential Radon Exposure? Results of a Pooling Study.
    Arch Bronconeumol. 2025 Oct 16:S0300-2896(25)00375.
    PubMed        
    
    

    
    Arch Pathol Lab Med

11. WATSON AS, Le C, Wertheimer A, Escobedo S, et al
    Precision Detection of FGFR2b Protein Expression in Solid Tumors.
    Arch Pathol Lab Med. 2025;149:1016-1021.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. FUETH M, Christoffel J, Harati K, Reinkemeier F, et al
    Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models.
    BMC Cancer. 2025;25:1680.
    PubMed         Abstract available
    
    
13. BAO T, Li X, Deng Y, Chen L, et al
    Comparing radiomics, deep learning, and fusion models for predicting occult pleural dissemination in patients with non-small cell lung cancer: a retrospective multicenter study.
    BMC Cancer. 2025;25:1670.
    PubMed         Abstract available
    
    
14. HIRAI T, Horie Y, Kitamura T
    Summary of present design of discrete choice experiments for patient preferences in lung cancer based on the ISPOR ESTIMATE checklist.
    BMC Cancer. 2025;25:1649.
    PubMed         Abstract available
    
    

    
    Br J Cancer

15. BAIRD L, Zhang L, Hidaka T, Xi L, et al
    Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs.
    Br J Cancer. 2025;133:1377-1390.
    PubMed         Abstract available
    
    
16. SCHELCH K, Maach N, Hashim M, Zitta B, et al
    Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.
    Br J Cancer. 2025;133:1391-1400.
    PubMed         Abstract available
    
    
17. LI W, Pei W, Wang Y, Nie J, et al
    Unraveling cellular dynamic changes in tumor evolution induced by long-term low dose-rate radiation.
    Br J Cancer. 2025;133:1278-1296.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

18. CUI L, Lee J, Miller J, Tang M, et al
    Design and creation of a racially diverse lung cancer registry with detailed genomic and environmental annotation.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Res

19. SOLANKI HS, Shah H, Imbody D, Desai B, et al
    RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activation in Non-Small Cell Lung Cancer.
    Cancer Res. 2025 Oct 30. doi: 10.1158/0008-5472.CAN-25-0600.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

20. KASSIE F, Wang K, Bang K, Chowdhury MRH, et al
    Lung cancer chemo-interception by sulfasalazine and disulfiram co-delivered using a nano self-emulsifying drug delivery system in mice.
    Carcinogenesis. 2025 Oct 28:bgaf075. doi: 10.1093.
    PubMed         Abstract available
    
    
21. SAMET JM, Richardson DB
    Uranium mining and lung cancer: a legacy of the nuclear age.
    Carcinogenesis. 2025;46:bgaf057.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

22. HO WLJ, Karipineni S, Ye JC
    Factors Associated With Local Control and Toxicity of Hypofractionated Radiotherapy for Early and Late-Stage Ultracentral Lung Tumors.
    Clin Lung Cancer. 2025;26:e572-e581.
    PubMed         Abstract available
    
    
23. CRAVEREAU O, Bourbonne V, Vaugier L, Lucia F, et al
    AFSOS-SFRO Guidelines on Radiation-Induced Lung Injury.
    Clin Lung Cancer. 2025;26:527-540.
    PubMed         Abstract available
    
    
24. ATTILI I, Pellizzari G, Bertolaccini L, Corvaja C, et al
    Actionable Gene Alterations in Resected Non-Small Cell Lung Cancer: Primary Results From the AGA-R Study.
    Clin Lung Cancer. 2025 Oct 3:S1525-7304(25)00240.
    PubMed         Abstract available
    
    
25. DAFFRE E, Bouam S, Strano S, Blanc K, et al
    Late Survival and Hospital Trajectory After Pneumonectomy for Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Oct 2:S1525-7304(25)00239.
    PubMed         Abstract available
    
    
26. MASAGO K, Kuroda H, Seto K, Sasaki E, et al
    Genomic Landscape of Resected Invasive Mucinous Adenocarcinoma of the Lung.
    Clin Lung Cancer. 2025;26:583-594.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

27. NIIMI T, Hattori A, Fukui M, Matsunaga T, et al
    Predictors and patterns of hilar lymph node metastasis by tumour location in clinical stage IA pure-solid non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Oct 27:ezaf361. doi: 10.1093.
    PubMed         Abstract available
    
    
28. SHIBAZAKI T, Mori S, Watanabe Y, Li L, et al
    Difference in Lung Volume Changes Following Each Lobectomy.
    Eur J Cardiothorac Surg. 2025;67:ezaf346.
    PubMed         Abstract available
    
    

    
    Int J Cancer

29. TAKAMORI S, Shimokawa M, Yamaguchi M, Mori M, et al
    Prospective validation study of nutritional and immunological predictors in immune checkpoint inhibitor efficacy for non-small cell lung cancer.
    Int J Cancer. 2025 Oct 26. doi: 10.1002/ijc.70170.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

30. WAN N, Yang C, Wang B, Guo Y, et al
    Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies.
    J Cancer Res Clin Oncol. 2025;151:306.
    PubMed         Abstract available
    
    
31. BEYON J, Collins JE, Welch CA, Kamran A, et al
    Immunotherapy with and without radiotherapy following the diagnosis of bone metastasis for stage IV non-small cell carcinoma.
    J Cancer Res Clin Oncol. 2025;151:309.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

32. LARA-MEJIA L, Cardona AF, Mas L, Martin C, et al
    Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
    J Thorac Oncol. 2025 Oct 27:S1556-0864(25)02849.
    PubMed        
    
    
33. ALLGAUER M, Kluck K, Christopoulos P, Ball M, et al
    Advancing Lung Cancer Staging: Integrating IASLC Recommendations and Bioinformatics to Delineate Tumor Origins.
    J Thorac Oncol. 2025 Oct 22:S1556-0864(25)02857.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

34. FUEREDER T, Garde-Noguera J, Garcia-Mosquera JJ, Ruiz-Borrego M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1454-1466.
    PubMed         Abstract available
    
    

    
    Lung Cancer

35. ISHIBASHI N, Nagata H, Yabe R, Ueda K, et al
    Prognostic impact of pleural lavage cytology in EGFR-stratified resected non-small cell lung cancer.
    Lung Cancer. 2025;209:108804.
    PubMed         Abstract available
    
    
36. AHN MJ, Lin SH, Yang CT, Lee JB, et al
    Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study.
    Lung Cancer. 2025;209:108748.
    PubMed         Abstract available
    
    
37. SEO J, Curran E, Whitty JA, Horn MK, et al
    Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertions.
    Lung Cancer. 2025;209:108796.
    PubMed         Abstract available
    
    
38. HUIJS JWJ, Ogliari FR, Damhuis RAM, Jongbloed M, et al
    Overall survival in patients with non-small cell lung cancer and leptomeningeal metastases: Data from the Dutch cancer Registry.
    Lung Cancer. 2025;209:108806.
    PubMed         Abstract available
    
    

    
    N Engl J Med

39. YANG JC, Lu S, Hayashi H, Felip E, et al
    Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2025;393:1681-1693.
    PubMed         Abstract available
    
    
40. DIMOU A, Mansfield A
    EGFR-Mutated Lung Cancer - Letting the Butterfly Out of the Cocoon.
    N Engl J Med. 2025;393:1743-1745.
    PubMed        
    
    

    
    Oncogene

41. REN Y, Ming R, Zuo A, Liu S, et al
    Cancer-associated fibroblasts drive lung adenocarcinoma progression via THBS2-mediated epithelial-mesenchymal transition.
    Oncogene. 2025;44:4284-4297.
    PubMed         Abstract available
    
    
42. TONG X, O'Kelly J, Xie D, Mori A, et al
    Retraction Note: Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway.
    Oncogene. 2025 Oct 28. doi: 10.1038/s41388-025-03615.
    PubMed        
    
    

    
    Oncologist

43. LIU G, Solomon BJ, Mazieres J, Kim DW, et al
    Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study.
    Oncologist. 2025;30:oyaf287.
    PubMed         Abstract available
    
    
44. SALOMONE F, Novero G, Ciani O, Ferrara R, et al
    Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.
    Oncologist. 2025;30:oyaf339.
    PubMed         Abstract available
    
    

    
    PLoS One

45. HUSSAIN T, Son EH, Wallen GR, Yang L, et al
    Symptom profiles in lung cancer survivors: A latent class approach.
    PLoS One. 2025;20:e0309272.
    PubMed         Abstract available
    
    
46. MOHAMED Z, Fofana S, Cobos E, Tripathi MK, et al
    Causal predictive modeling of survival of lung and bronchus cancer patients diagnosed during 2010-2011 in Texas.
    PLoS One. 2025;20:e0333477.
    PubMed         Abstract available
    
    
47. HOSSEINI E, Tavakoli-Yaraki M, Meamar AR, Ajam Z, et al
    Impact of hydatid cyst laminated layer antigens on cell death rate, apoptosis induction, and key genes in the cell proliferation pathway: Insights from A549 cell line studies.
    PLoS One. 2025;20:e0335188.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

48. CUI H, Cai X, Qian Q, Fan S, et al
    ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2502778122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.